DanielLebovicMD

Oncology • Grosse Pointe Woods, MI

Physician

Join to view full profile

Dr. Lebovic is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lebovic's full profile

Already have an account?

Office
19229 Mack Ave
Ste 24
Grosse Pointe Woods, MI 48236
Phone+1 313-884-5522

Fax+1 313-884-6054

Education & Training

University of MichiganFellowship, Hematology and Medical Oncology, 2006 - 2009
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2002 - 2006
University of Toronto Faculty of MedicineClass of 2002

Certifications & Licensure

MI State Medical License 2006 - 2024
NY State Medical License 2004 - 2009
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma Start of enrollment: 2011 Jul 01
Terminated
Phase 2
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma Start of enrollment: 2012 Apr 25
Completed
Phase 1
A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL Start of enrollment: 2012 Nov 01
Active, not recruiting
Phase 2
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2
A Study of Opaganib in Coronavirus Disease 2019 Pneumonia Start of enrollment: 2020 Jul 02
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

342 citations
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Andrzej Jakubowiak, Dominik Dytfeld, Kent A. Griffith, Daniel Lebovic, David H. Vesole
Blood. 2012-08-30
153 citations
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
Jatin J. Shah, Andrzej Jakubowiak, Owen A. O'Connor, Robert Z. Orlowski, R. Donald Harvey
Clinical Cancer Research. 2016-01-01
129 citations
Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.
Hongxiu Li, Mark S. Kaminski, Yifeng Li, Mehmet Yildiz, Peter Ouillette
Blood. 2014-03-06

Press Mentions

TCF Bank Sponsors Blood Drive for COVID-19 TreatmentMay 5th, 2020